SRZN Surrozen Inc

Price (delayed)

$24.45

Market cap

$283.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$41.34

Enterprise value

$183.05M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 89
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 16

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various ...

Highlights
SRZN's quick ratio is up by 30% since the previous quarter and by 19% year-on-year
Surrozen's gross profit has surged by 116% QoQ but it has decreased by 36% YoY
Surrozen's revenue has soared by 116% from the previous quarter but it has decreased by 36% YoY
Surrozen's EPS has plunged by 66% YoY and by 28% from the previous quarter
Surrozen's net income has decreased by 49% QoQ

Key stats

What are the main financial stats of SRZN

SRZN stock price

How has the Surrozen stock price performed over time
Intraday
-0.49%
1 week
-6.54%
1 month
-23.76%
1 year
194.22%
YTD
8.19%
QTD
-16.07%

Financial performance

How have Surrozen's revenue and profit performed over time
Revenue
$7.49M
Gross profit
$7.49M
Operating income
-$43M
Net income
-$360.5M
Gross margin
100%
Net margin
-4,810.5%
Surrozen's operating margin has plunged by 157% YoY but it has soared by 53% from the previous quarter
Surrozen's gross profit has surged by 116% QoQ but it has decreased by 36% YoY
Surrozen's revenue has soared by 116% from the previous quarter but it has decreased by 36% YoY
Surrozen's operating income has shrunk by 66% YoY and by 2.2% QoQ

Price vs fundamentals

How does SRZN's price correlate with its fundamentals

Growth

What is Surrozen's growth rate over time

Valuation

What is Surrozen stock price valuation
P/E
N/A
P/B
N/A
P/S
35.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.43
Surrozen's EPS has plunged by 66% YoY and by 28% from the previous quarter
Surrozen's equity has decreased by 48% from the previous quarter
Surrozen's revenue has soared by 116% from the previous quarter but it has decreased by 36% YoY
SRZN's price to sales (P/S) is 12% higher than its last 4 quarters average of 32.0

Efficiency

How efficient is Surrozen business performance
SRZN's ROA has shrunk by 172% YoY and by 47% QoQ
SRZN's ROIC is down by 47% QoQ
Surrozen's ROS has increased by 31% from the previous quarter

Dividends

What is SRZN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRZN.

Financial health

How did Surrozen financials performed over time
The total assets is 70% less than the total liabilities
Surrozen's total liabilities has increased by 39% from the previous quarter
SRZN's quick ratio is up by 30% since the previous quarter and by 19% year-on-year
The debt is 102% more than the equity
The debt to equity has plunged by 101% YoY but it has soared by 50% from the previous quarter
Surrozen's equity has decreased by 48% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.